Pulmonx Corporation has announced a 6% increase in revenue for the third quarter of 2026, marking a significant recovery in its financial performance. The company reported total worldwide revenue of $22.8 million for the quarter, compared to $21.5 million in the same period last year. This growth indicates a positive trend for Pulmonx as it continues to navigate the challenges of the surgical and medical instruments industry.

Founded in Delaware, Pulmonx Corp (Nasdaq: LUNG) specializes in minimally invasive treatments for lung disease. The company operates under the Standard Industrial Classification (SIC) code 3841, which encompasses surgical and medical instruments and apparatus. Its recent filings include an 8-K report dated October 27, 2026, detailing its financial results for the third fiscal quarter.

According to the filing, Pulmonx's revenue growth was driven by a 7% increase in U.S. revenue, which reached $14.9 million. International revenue also saw a 5% rise, totaling $7.9 million, despite challenges in the Chinese market. The company noted that excluding China, international revenue growth was 9% year-over-year on both a GAAP and constant currency basis.

“We are very pleased to have returned to year-over-year revenue growth in the third quarter,” said Glen French, President and Chief Executive Officer of Pulmonx.

The filing highlights a gross margin of 76% for the quarter, up from 75% in the previous year. Additionally, Pulmonx reported a net loss of $8.4 million, significantly reduced from a loss of $14.0 million in the same quarter of 2025. The company also achieved a 57% reduction in Adjusted EBITDA loss, indicating improved operational efficiency.

This financial performance may impact various stakeholders, including investors, employees, and healthcare providers, as Pulmonx continues to execute its commercial strategy and advance clinical initiatives. The company has expressed confidence in its ability to build on this momentum and deliver growth while focusing on long-term strategic priorities.

Looking ahead, Pulmonx expects total revenue for the full year 2026 to fall within the range of $90 million to $92 million. The company also anticipates a gross margin of approximately 77% for the year and a decrease in cash and cash equivalents by about $22 million, assuming no additional drawdowns under its credit facility.

The company has scheduled a conference call for today, October 27, 2026, at 1:30 p.m. PT to discuss its third-quarter financial results in detail. Investors can access a live webcast of the call on the Investor Relations section of Pulmonx's website.